AstraZeneca's Enhertu Cancer Treatment Reduced Risk of Disease Progression by 72%
September 20 2021 - 2:48AM
Dow Jones News
By Anthony O. Goriainoff
AstraZeneca PLC said Monday that its cancer treatment Enhertu
reduced the risk of disease progression or death by 72% in patients
with HER2-positive metastatic breast cancer.
HER2 refers to a breast cancer that tests positive for a protein
called human epidermal growth factor receptor 2.
The U.K. pharmaceutical giant said that the DESTINY-Breast03
Phase 3 trial showed that Enhertu demonstrated superior
progression-free survival versus trastuzumab emtansine, a
HER2-directed antibody drug conjugate currently approved to treat
patients with HER2-positive unresectable--unable to be removed by
surgery--and/or metastatic breast cancer previously treated with
trastuzumab and a taxane--a type of drug that blocks cell
growth.
"The high and consistent benefit seen across efficacy endpoints
and key subgroups of patients receiving Enhertu in DESTINY-Breast03
is remarkable and supports the potential of Enhertu to become the
new standard of care for those who have previously been treated for
HER2-positive metastatic breast cancer," the company said.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
September 20, 2021 02:33 ET (06:33 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From May 2023 to May 2024